XL092-311 Zanzalintinib vs everolimus in metastatic neuroendocrine tumors - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to compare the performance of 2 drugs: zanzalintinib and everolimus. We want to know which option is the most effective for treating neuroendocrine tumors.

¿Cuál es la Condición que se está estudiando?

Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine

Tumores

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with locally advanced (cannot be removed by surgery) or metastatic (has spread) neuroendocrine tumor
Have failed to adequately respond to previous treatment

For more information, contact the study team at carolann.wiggs@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join the study, you will get a random assignment (like a coin flip) to either take zanzalintinib or everolimus once per day. Both drugs are taken by mouth.

Your study regimen will last for as long as the study doctor believes that you are getting a positive benefit.

Detalles del Estudio

Título Completo

A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors (XL092-311)

Investigador Principal